The NEWDIGS FoCUS consortium of multiple stakeholders (payers, providers, patient advocacy organizations, pharmaceutical developers, academics and others) has been working collaboratively since 2016 to address the need for new, innovative financing and reimbursement models for durable/potentially curative therapies in the US to ensure patient access and sustainability for all stakeholders. This white paper explores practices and tools that can help make these therapies accessible and sustainable.